
CONNECT - et økosystem for offentlig-privat samarbeid i presisjonsmedisin for kreft

Joint objectives and shared opportunities for public and private stakeholders

In the Commission documents for 2019 and 2020, the **Norwegian Minister of Health** has explicitly asked for initiatives that can **accelerate the implementation of precision medicine** both, in research and standard patient care.

A Public-Private Consortium can address the different and interconnected tasks that require a **coalition of resources, expertise and partnering** and which are beyond the capacity and resources of a single organization.



Implementing precision cancer medicine in Norway: four interconnected initiatives:

InPreD Norway:

National infrastructure for precision diagnostics

IMPRESS-Norway:

Improving public cancer care by implementing precision medicine in Norway


INSIGHT:

Regulatory framework for implementing precision medicine into the Norwegian health care system

CONNECT:

Norwegian Precision Cancer Medicine Implementation Consortium

National infrastructure for precision diagnostics, InPreD Norway




The six pathology departments at the university hospitals as core of InPreD-Norway

- Network for NGS accessible for all pathology departments being established
- Patient recruitment to clinical trials is available for all hospitals.

Aim: Equal access to expanded molecular testing – and experimental treatment for cancer patients

InPreD: Diagnosis and assessment for cancer patients where experimental treatment and clinical trial inclusion is an option




IMPRESs-Norway: Study Outline

- Opportunity for all Norwegian cancer patients
- Entry by testing (level 1 lab / 500-gene panel test)
- Evaluation via national molecular tumor board (MTB)
 - Amalgamated algorithm defined by inclusion criteria for each drug
- If suitable molecular profile
 - Referral to other ongoing trial
 - Inclusion in IMPRESs-Norway study-arm
- Sampling biological material (tumor/pleura fluid/ascites/blood)
- RECIST or other standard evaluation (for different diagnoses)
- Monitoring according to GCP
- Study protocol complemented with drug-specific study manual
 - Definition of inclusion criteria, sampling, translational research for each drug



Study-design: combined umbrella-basket, Simon two-stage model



- Eligible patients with identified actionable targets with matching drug from the study drug portfolio will be included in an IMPRESS-Norway cohort.
- A cohort will consist of patients with the same indication and same actionable target.
- IMPRESS-Norway will open several cohorts and expand these to the next stage based on the response determined in the patient group.

For reference also see: van der Velden, D.L., Hoes, L.R., van der Wijngaart, H. *et al.* The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. *Nature* **574**, 127–131 (2019) Van Waalwijk *et al.* Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients. *Annals of Oncology*, *30*(5), 663–665 (2019)

IMPRESs-NORWAY: 1:1 Meetings with Pharma Companies from March 2020

AbbVie Astra Zeneca Bayer BMS Merck Serono MSD Novartis Pfizer Roche Sanofi Amgen Astellas GSK Takeda Karyopharm (initial discussion) **Blueprint medicines** Eli Lilly

April 2020 – June 2020: Internal evaluation Autumn 2020 – Individual process with each company for development of drug specific manuals and approval of drugs

- Company-specific processes
- Involvement of and decision making on Nordic, European, Global level within Pharma
- Individual follow-up by OUH team in close collaboration with OCC

INSIGHT – Work Packages

WP1: Statistical analysis in non-randomized trials

PI: Inge Christoffer Olsen

WP2: Cost-effectiveness of IMPRESS-Norway PI: Eline Aas

WP3: Drug reimbursement scheme

PI: Tor Iversen

WP4: Ethical challenges embedded in the PCM PI: Bjørn Hofmann

WP5: Insecurity in health care legislation PI: Anne Kjersti Befring


WP6: Decision process and patient communication PI: Per Magnus Mæhle

WP7: Interface to IMPRESS, InPreD & CONNECT PI: Kjetil Taskén

- Develop syntethic control groups
- Statistical framework IMPRESS-Norway
- Framework for merging control groups for optimalization of syntetich control groups
- Health outcomes IMPRESS-Norway
- Costs for patients in the IMPRESS-pathway
- Cost-effectivness analyses
- Equal access
- State-of-the-art reimbursement scheme
- Propose new schemes to be tested in IMPRESS-Norway
- Comperison of impact from both public and private perspective of different schemes
- Describe the generic uncertainty
- Research ethics (e.g. real consent from vulnerable patients)
- Describe methodlogical issues (e.g. Assessing causlity using small patientsgroups)
- Legal framework for access, process and store molecular data without consent
- Merging legal framework covering standard of care at explorative research-based treatment
- Decision dynamics in IMPRESS-Norway
- Exploring communication of missions, opportunities, recommendations and uncertainty to the patient.
- Dissemination strategy (inter-project and external)
- Participation in Working Groups in CONNECT
- Interface IMPRESS-Norway and InPreD

CONNECT Public Private Partnership:

Offering an arena for all relevant stakeholders to jointly address key obstacles and piloting novel solutions



CONNECT - Public and private collaboration within the health care sector

Benefits for Public Partners:

- National harmonization of molecular testing
- Access to industry competence and contribution
- Increase number of clinical trials
- Sustainable system ready for next level of precision medicine
- Advisory for large scale projects such as InPreD and IMPRESs

Benefits for Private Partners:

- Infrastructure for national stratification
- Increase competence key for attracting clinical trials
- Increased research and infrastructure
- Precompetitive forum for implementation



Joint benefits for all stakeholders

- Faster and equal access to novel treatments
- Enrich Cancer Registry data for STA/HTA assessments of precision medicine
- Proactive communication for competence building
- Informed discussion of novel implementation and reimbursement methods